A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer
NCT02671955
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
12
Enrollment
INDUSTRY
Sponsor class
Stopped
Janssen business decision
Conditions
Advanced Cancer
Interventions
DRUG:
JNJ-61610588
Sponsor
Janssen Research & Development, LLC